Torasemid: the pathway in the body

Torasemid is part of the pathway “Torasemid”. This page shows the whole pathway; the station of Torasemid is highlighted.

Where this laboratory value sits: Torasemide — tablet, swallowed. Torasemide is swallowed as a tablet and absorbed rapidly from the bowel. The liver holds back little on the first pass; most of it reaches the blood unchanged and is broken down in the liver later. It inhibits NKCC2 in the loop. Source 7, 8

In brief

Torasemide is a loop diuretic. It acts not from the blood but from the urine side: there it binds to the Na-K-2Cl co-transporter in the thick ascending part of the loop of Henle and halts its passage. More salt and water thus pass into the urine.

What this is about

The loop of Henle is a section of the kidney tubule. In its thick ascending part the kidney reclaims a large share of the salts from the filtrate. Four things mesh there:

The co-transporter NKCC2 in the wall facing the lumen carries sodium, potassium and two chloride into the cell at once. It is driven not by energy of its own but by the sodium gradient that the sodium-potassium pump holds on the blood side.
A large share of the potassium returns at once to the lumen through the channel ROMK. Without this return path the co-transporter would run out of potassium.
Because positive charge travels into the lumen continuously in doing so, the lumen is positively charged against the tissue.
It is precisely this voltage that pushes magnesium and calcium back into the blood between the cells, through pores of claudin-16 and claudin-19.

Torasemide reaches this section not through the blood but through the urine: because it is almost entirely bound to protein in the blood, it is hardly filtered; carriers in the proximal tubule move it actively into the fluid of the tubules. From there it binds to the co-transporter. What is halted is the passage of this one carrier: sodium, potassium and chloride are no longer reclaimed together here and flow onward — and because the voltage in the lumen hangs on that very reclaim, the path of magnesium and calcium between the cells changes as well.

What this means in an individual case depends on many things and belongs in a conversation with a doctor or health practitioner.

Source 1, 2, 3, 4, 5, 8

11 stations · 9 sources

Swipe the graphic sideways

The pathway step by step

Each station states what the compound does there. Three signs: ↑ supplies — builds up or makes available · ↓ depletes — inhibits, consumes or withholds · ↕ both, depending on amount. Behind it stands what the statement rests on: established physiology, observed in studies, or contested. The signs do not grade; they name the direction.

Torasemide → In the blood In the blood torasemide hangs almost entirely on proteins. Very little of it therefore passes into the filtrate in the kidney — through the filter alone the substance would hardly reach its site of action. This keeps it in the bloodstream. Source 7, 8↑ supplies Binding to protein keeps the substance in the bloodstream instead of spreading it into the tissues. It thus stays where the carriers of the kidney can collect it. established physiology Source 7, 8
⚖ When the balance tips

too much — If a lot of active substance is present in the blood, liver enzymes break it down and the kidney's carriers pass more of it into the urine; both lower the level again.

too little — If little active substance is present in the blood, little reaches the carriers in the proximal tubule, and hardly any arrives at NKCC2.

established physiology · Source 7, 8
In the blood → Proximal tubule carriers for acids Instead, carriers for organic acids move the substance actively out of the blood into the fluid of the kidney tubules. The label names this secretion as the main route by which torasemide gets into the urine. This is how it reaches its site of action. Source 7, 8↑ supplies The carriers for organic acids are the actual feeders. They actively bring the substance to where it acts: into the fluid of the kidney tubules. established physiology Source 7, 8
⚖ When the balance tips

too much — If the carriers move a lot of the substance, more arrives in the tubular fluid, and more of it reaches NKCC2 in the loop.

too little — If the carriers move little, the substance stays in the blood and hardly arrives at the site of action; through the filter alone almost none gets there.

established physiology · Source 7, 8, 1
Proximal tubule → In the tubular urine With the urine torasemide flows on into the loop of Henle. It acts from inside, out of the lumen of the tubule; the label describes exactly this site of action. Only what arrives here reaches NKCC2. Source 1, 8↑ supplies What counts for the action is what arrives in the lumen of the tubule: only from there does the substance reach the binding site on NKCC2. established physiology Source 1, 8
⚖ When the balance tips

too much — If there is a lot of the substance in the tubular fluid, almost all NKCC2 are occupied; more of it then changes nothing further at the transporter.

too little — If there is little of the substance in the tubular fluid, most NKCC2 stay free, and the loop reclaims most of the ions.

established physiology · Source 1, 8
Urine in the loop → Drawn into the cell NKCC2 The co-transporter draws the three kinds of ion into the cell together. It needs no energy of its own: it is driven by the sodium gradient that the sodium-potassium pump maintains on the blood side. Water does not follow here; the urine is diluted. Source 1, 6↑ supplies The salt brought in passes on into the blood and the renal medulla. As this segment lets no water through, the fluid in the tubule is left diluted. established physiology Source 1
⚖ When the balance tips

too much — If NKCC2 brings in a lot, the renal medulla becomes richer in salt and the tubular fluid more diluted; the kidney can later concentrate the urine more strongly.

too little — If little enters the cell because NKCC2 is occupied, the salt stays in the urine and carries water with it; the medulla becomes poorer in salt, and the urine can be concentrated less.

established physiology · Source 1, 8
Drawn into the cell → Sodium to the blood Na-K pump · ATP, magnesium On the blood side the sodium-potassium pump moves sodium out of the cell by splitting ATP; chloride leaves there through channels of its own. The gradient on which the co-transporter lives is thus kept up. With little ATP, the gradient flattens. Source 1, 5↑ supplies The pump keeps sodium low inside the cell and thus provides the drive for NKCC2. It is the step in this sequence that draws its energy from ATP. established physiology Source 5, 1
⚖ When the balance tips

too much — If the pump works hard, sodium in the cell falls and the gradient for NKCC2 becomes steeper; at the same time it brings more potassium into the cell.

too little — If little ATP is available to the pump, sodium in the cell rises, the gradient flattens, and NKCC2 brings in fewer ions.

established physiology · Source 5, 1
Drawn into the cell → Potassium to the lumen ROMK A large share of the potassium drawn in returns at once to the lumen through the channel ROMK. Without this return path the co-transporter would run out of potassium, for the urine holds far less of it than of sodium. This creates the voltage in the lumen. Source 1, 4↑ supplies The return path through ROMK keeps resupplying the co-transporter with potassium and brings positive charge into the lumen. The lumen-positive voltage arises from this. established physiology Source 1, 4
⚖ When the balance tips

too much — If a lot of potassium flows back through ROMK, the positive charge in the lumen rises, and the push on magnesium and calcium between the cells becomes stronger.

too little — If little potassium flows back, NKCC2 runs out of potassium, and the reclaim of sodium and chloride in this segment stalls.

established physiology · Source 1, 2
Potassium to the lumen → Lumen-positive voltage Because positive charge travels back into the lumen continuously, a voltage arises between lumen and blood side: the lumen is positively charged against the tissue. It drives magnesium and calcium back into the blood. Source 1, 2↑ supplies The voltage is the drive for the reclaim of magnesium and calcium between the cells. Without energy of its own, the segment thus reclaims a large share of them. established physiology Source 2, 3
⚖ When the balance tips

too much — If the voltage is high, more magnesium and calcium are pushed back through the pores, and less of them enters the urine.

too little — If the voltage collapses, for instance when NKCC2 is occupied, the drive falls away; magnesium and calcium stay in the urine and leave in greater amounts.

established physiology · Source 2, 3
Lumen-positive voltage → Magnesium and calcium claudin-16 and -19 This voltage pushes magnesium and calcium back into the blood between the cells. The passage for it is formed by the proteins claudin-16 and claudin-19. Where the voltage is absent, this path is absent too. With NKCC2 occupied, more of both enters the urine. Source 2, 3↑ supplies Along this path between the cells the kidney returns a large share of the filtered magnesium and part of the calcium to the blood. established physiology Source 2, 3
⚖ When the balance tips

too much — If there is a lot of calcium in the blood, the calcium sensor CaSR signals this to the cell; it then inserts claudin-14, which narrows the pores, and more enters the urine.

too little — If there is little calcium in the blood, the CaSR sensor stays quiet, the pores stay open, and more calcium and magnesium are reclaimed.

established physiology · Source 2

Further stations

Torasemide — tablet, swallowed Torasemide is swallowed as a tablet and absorbed rapidly from the bowel. The liver holds back little on the first pass; most of it reaches the blood unchanged and is broken down in the liver later. It inhibits NKCC2 in the loop. Source 7, 8↓ depletes Torasemide inhibits the Na-K-2Cl co-transporter in the loop of Henle. Once it reaches the urine there, sodium, potassium and chloride stay in the tubule, and water passes into the urine with the salt. established physiology Source 8, 1
⚖ When the balance tips

too much — If a lot of active substance is present, a larger share of NKCC2 is occupied; more sodium and chloride, and with them more water, pass into the urine.

too little — If little active substance is present, most NKCC2 stay free, and the loop reclaims sodium, potassium and chloride as usual.

established physiology · Source 8, 1
NKCC2 — Na-K-2Cl co-transporter In the wall facing the lumen sits the co-transporter NKCC2. At each cycle it carries one sodium, one potassium and two chloride ions along together. Torasemide binds to it and brings this cycle to a halt. Sodium and chloride then stay in the urine. Source 1, 6, 8↓ depletes With NKCC2 occupied, sodium, potassium and chloride stay in the urine. At the same time the lumen-positive voltage that pushes magnesium and calcium back between the cells falls away. established physiology Source 1, 2, 8
⚖ When the balance tips

too much — If a lot of NKCC2 is built into the wall and switched on by attached phosphate, the loop reclaims more salt, and less sodium arrives further along.

too little — If little NKCC2 is active, more salt reaches the later segments; there more sodium is exchanged for potassium, and the urine can be concentrated less.

established physiology · Source 6, 1, 4
Urine in the loop — sodium, potassium, chloride The filtrate from the glomerulus carries sodium, potassium and chloride with it. In the thick ascending part of the loop of Henle a large share of these ions is reclaimed into the cells of the wall. From them the loop builds the medullary salt gradient. Source 1↑ supplies The salt in the fluid of the loop is the material from which the thick part builds the salt gradient in the renal medulla. Without this gradient the kidney cannot concentrate the urine. established physiology Source 1
⚖ When the balance tips

too much — If a lot of salt arrives in the loop, NKCC2 reclaims more of it; what exceeds that flows on into the convoluted part.

too little — If little salt arrives, the loop reclaims little; the macula densa at the end of the thick part detects this and sets filtration in the associated glomerulus higher.

established physiology · Source 1

What the co-transporter reclaims

Sodium — The co-transporter draws sodium out of the urine into the cell; with it occupied, this reclaim does not happen Source 1, 8
Potassium — Rides along in the co-transporter and returns to the lumen through ROMK; both hang on the same cycle Source 1, 4
Chloride — Two chloride ions ride into the cell at each cycle of the co-transporter; with it occupied, it stays in the urine Source 1, 8
Magnesium — Is reclaimed between the cells of the loop, pushed by the lumen-positive voltage; without the voltage, less Source 2, 3
Calcium — Takes the same path between the cells as magnesium, through the pores of claudin-16 and claudin-19 Source 2

What takes part in these steps

ATP — Energy source of the sodium-potassium pump on the blood side, which keeps the gradient for the co-transporter Source 5

What the prescribing information states

Trials in the United States with 564 participants on torasemide and 274 on placebo. The prescribing information carries no per-reaction frequency table here; it names only the few comparative figures below. A column for an active comparator is likewise absent — at this place the prescribing information carries no third group.

How to read the table: what matters is the comparison within the row, not the single figure. Three points belong with it — the first row is the only single reaction for which the prescribing information gives any comparison with placebo at all. The second and third rows are lower on torasemide than on placebo. And the third row comes from another part of the same section, from controlled trials in the United States over six weeks; the prescribing information does not name their participant count there, so the column header does not fit that row exactly.

	Torasemide (564)	Placebo (274)
Excessive urination	6.7%	2.2%
Stopped because of adverse events	3.5%	4.4%
Low potassium value in the laboratory	1.5%	3%

Further reactions have been reported after approval. The prescribing information notes that neither a frequency nor a causal relationship can be derived from such reports; they are therefore not listed here.

Sources

Mount DB. Thick ascending limb of the loop of Henle. Clin J Am Soc Nephrol 2014 · PubMed 25318757
Alexander RT, Dimke H. Molecular mechanisms underlying paracellular calcium and magnesium reabsorption in the proximal tubule and thick ascending limb. Ann N Y Acad Sci 2022 · PubMed 36200584
de Baaij JHF. Magnesium reabsorption in the kidney. Am J Physiol Renal Physiol 2023 · PubMed 36633869
Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol 2015 · PubMed 24721891
Clausen MV, Hilbers F, Poulsen H. The Structure and Function of the Na,K-ATPase Isoforms in Health and Disease. Front Physiol 2017 · PubMed 28634454
Maskey D, Granados Pineda J, Ortiz PA. Update on NKCC2 regulation in the thick ascending limb (TAL) by membrane trafficking, phosphorylation, and protein-protein interactions. Front Physiol 2024 · PubMed 39717823
Sherazi AW, Zamir A, Rehman AU et al. A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. Ther Drug Monit 2024 · PubMed 38176856
US prescribing information (United States): Torsemide Tablets, DailyMed, version of 2 April 2026, sections 11 Description, 12.1 Mechanism of Action and 12.3 Pharmacokinetics · Prescribing information
US prescribing information (United States): Torsemide Tablets, DailyMed, version of 2 April 2026, sections 6.1 Clinical Trials Experience and 6.2 Postmarketing Experience · Prescribing information

Whole pathway: Torasemid

As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice Privacy policy All biomarkers